Clinical-stage biotechnology company Cellectis (Euronext Growth Paris:ALCLS) (NASDAQ:CLLS) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designation for its UCART22 product candidate targeting Acute Lymphoblastic Leukemia (ALL).
ALL, representing 10% of US leukemia cases, progresses rapidly and is typically fatal within weeks or months if left untreated. UCART22 aims to address an urgent need for new therapies for ALL patients who are ineligible for or relapsing after standard treatments.
These FDA designations mark a significant step towards developing allogeneic CAR T products that would be readily available for all patients.
Cellectis expects to provide study updates by the end of the year.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval